Ultragenyx shareholders OK 14.5M-share equity plan; re-elect directors

Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions 84,551,399 221,802 13,187

Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company’s stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,659,150 22,888,600 26,748 11,211,890

Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 72,517,613 1,056,885 11,211,890 Shehnaaz Suliman, M.D. 65,801,638 7,772,860 11,211,890 Daniel G. Welch 66,301,426 7,273,072 11,211,890

Proposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,945,277 2,594,517 34,704 11,211,890